Corbion, the global sustainable ingredients company based in Amsterdam, and BRAIN Biotech AG, headquartered in Zwingenberg, Germany, have reached agreement to collaborate in the development of novel biobased antimicrobial compounds and its derivatives. This collaboration will accelerate Corbion’s efforts to deliver enabling preservation capabilities to food manufacturers that also resonate with consumers looking for food products based on natural ingredients.
“At Corbion, advancing the state of the art in nature-based ingredient technologies, proving and expanding on their value and efficacy, is essential to preserving what matters,” said Domenico Vulcano, Vice President of Global Innovation at Corbion. “One of the ways we continue to strengthen our investment in innovation is through establishing partnerships with other experts like those at BRAIN Biotech. We believe this kind of collaboration will help us bring the next paradigm-changing breakthroughs to market sooner.”
BRAIN Biotech AG brings to the collaboration expertise in specialty enzyme technology, microbial strain development, and bioprocess development. Additionally, it operates as a technology licensing company. Corbion brings advanced knowledge of food systems and biobased preservation technologies, intimate customer and industry-specific insights, and leading-edge piloting and scale-up capabilities.
“We are very pleased to partner with Corbion in expanding what’s possible with sustainable, bio-based solutions,” said Dr. Martin Langer, Managing Director & Executive Vice President at BRAIN Biotech AG. “We see a very strong affinity between our team at BRAIN and our collaborators at Corbion. Given our respective strengths, shared vision, and complementary areas of expertise, we expect this to be a fruitful collaboration that will deliver real impact for the world’s food manufacturers.”
